Shares in Intersect ENT (NSDQ:XENT) held steady today after the company reported preliminary data for its fourth quarter and full-year revenues.
The Menlo Park, Calif.-based company said it expects to reel in $96.1 – $96.3 million in revenue for the full year of 2017, up 22% from 2016. Intersect also pegged its fourth-quarter revenue between $29.3 million and $29.5 million, up 21% compared to the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Intersect ENT reports Q4, full-year revenue prelims appeared first on MassDevice.